Targeting a diverse spectrum of cancers.

Kinase switch control inhibitors for tumor-targeted and immune-targeted cancer therapies.

Platform

Deciphera’s proprietary switch control platform has generated a diverse clinical pipeline of kinase inhibitor drug candidates including tumor-targeted therapies and immuno-targeted therapies.

Investors

DCPH

$22.26

-4.97
10/19/18 4:00 PM EDT
© Nasdaq. Minimum 15 minutes delayed.

Latest News

Oct
19
2018
Deciphera Pharmaceuticals Reports Updated Preliminary Phase 1 Clinical Study Results with DCC-2618 at the European Society of Medical Oncology (ESMO) 2018 Congress Read More »
Sep
25
2018
Deciphera Pharmaceuticals, Inc. to Present at the 2018 Cantor Global Healthcare Conference Read More »
Sep
18
2018
Deciphera Pharmaceuticals Appoints Daniel C. Martin as Chief Commercial Officer Read More »